Antitumor Activity of Zanidatamab with Palbociclib and Fulvestrant in HER2+ Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Antitumor Activity of Zanidatamab with Palbociclib and Fulvestrant in HER2+ Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial
Zanidatamab (ZW25), a HER2-targeted Bispecific Antibody, in Combination with Chemotherapy (chemo) for HER2-positive Breast Cancer (BC): Results from a Phase 1 Trial
Zanidatamab in Combination with Evorpacept in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204)
Zanidatamab in Combination with Evorpacept in Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-expressing Cancers, Including Breast Cancer: a Phase 1b/2, Multicenter, Open-Label, Dose-Finding and Cohort-Expansion Study (ZWI-ZW25-204)